Search Results for: Alize Pharma II Acquired by
Articles
XOMA Expands its Commercial Royalty & Milestone Portfolio With DSUVIA Acquisition January 18, 2024
XOMA Corporation recently announced it has acquired an economic interest in DSUVIA (sufentanil sublingual tablet) from Talphera, Inc., for $8...Henlius & Sermonix Announce Strategic Collaboration & Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene January 11, 2024
Sermonix Pharmaceuticals Inc. and Shanghai Henlius Biotech, Inc. recently announced a strategic collaboration agreement in which Henlius will receive exclusive...Antabio Announces First Subjects Dosed in Phase 1 Clinical Trial of Highly Differentiated Antibiotic for Severe Hospital Infections May 25, 2023
Antabio SAS recently announces dosing of the first subjects in its Phase 1 clinical trial of MEM-ANT3310, a next- generation...Microcarrier Market is Expected to Reach $2.9 Billion April 13, 2023
The microcarrier industry is expected to grow significantly in the near future. This is due to the increasing demand for...INFLAMMASOME INHIBITORS - 21st Century Miracle Drugs: Spotlight on Clinical NLRP3 Inflammasome Inhibitors April 3, 2023
Bryan Oronsky, PhD, says traditionally, pharmaceutical development is based on the “magic bullet” concept of “one drug, one target, one disease.” However, with the growing realization that chronic inflammation lies at the center of many, if not all, diseases, it is possible to envision inflammasome inhibitors, which reduce or prevent inflammation, as near-universal treatment panaceas.
Sermonix’s Lasofoxifene Improves Vaginal/Vulvar Symptoms Relative to Fulvestrant in ELAINE 1 Study of Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 Mutation March 6, 2023
Sermonix Pharmaceuticals Inc. recently announced that its lead drug candidate, lasofoxifene, improved vaginal/vulvar symptoms while fulvestrant worsened them in a study...Incannex Engages Eurofins to Manufacture Novel Addiction Treatments CannQuit-N and CannQuit-O November 28, 2022
Incannex Healthcare Limited recently announced it has engaged multinational contract development and manufacturing organisation (CDMO) Eurofins Scientific to manufacture Incannex’s two distinct medicated….
SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: Understanding Critical Attributes Earlier in Development Leads to a More Robust Drug Product June 1, 2022
Contributor Cindy H. Dubin speaks with industry leaders on how drug sponsors and CDMOs are collaborating earlier, and highlights how third-party contractors are navigating material shortages and how the industry is shifting to address different therapeutic targets and molecules, such as mRNA.
SYNTHETIC ANTI-INFECTIVES - Synthetic Polymers Offer a New Class of Anti-Infectives June 1, 2022
James Graham believes synthetic anti-infectives offer a potential solution to the obstacles encountered by naturally derived antibiotics in the constant arms race against antimicrobial resistance.
Vaccitech Acquires Avidea Technologies to Expand Product Pipeline & Strengthen Scientific Leadership in Immunotherapies & Vaccines December 13, 2021
Vaccitech plc recently announced that it has acquired US-based Avidea Technologies, Inc. The consideration to Avidea’s existing shareholders is $40 million….
DRUG DEVELOPMENT EXECUTIVE - Quotient Sciences: Breaking Down the Silos Between Drug Substance & Drug Product June 1, 2021
Mark Egerton, PhD, CEO of Quotient Sciences, discusses how integrating these capabilities cuts through functional silos, simplifies drug development, and affirms Quotient’s belief that molecules need to become cures, fast.
AskBio Announces First Patient Dosed in Phase 1 Trial February 6, 2020
Asklepios BioPharmaceutical (AskBio) and its NanoCor Therapeutics subsidiary recently announced that the first patient has been dosed in a Phase...SPECIAL FEATURE - Outsourcing Analytical Testing: Novel Services Elicit Consistent, Quantifiable, & Faster Results January 14, 2020
Contributor Cindy H. Dubin, in her latest report, describes some novel analytical testing services aimed at ensuring quality and safety, and in some cases, speeding the process and saving money.
MilliporeSigma Acquires BSSN Software to Accelerate Customers’ Digital Transformation in the Lab August 7, 2019
MilliporeSigma has acquired BSSN Software, a Darmstadt, Germany-based laboratory informatics company that makes data more readily accessible for ease of integration, collaboration, analysis and…..
Genesis Drug Discovery & Development Expands Preclinical Contract Research Portfolio With Acquisition June 19, 2019
Genesis Drug Discovery & Development (GD3), the contract research organization (CRO) of Genesis Biotechnology Group (GBG), recently announced that it has expanded...REGENERATIVE MEDICINE - Cell Therapy - The Quest for Finding the Cure November 12, 2018
Aarti Chitale, MBA, believes as the therapeutic landscape evolves and transitions toward personalized and value-based care, regenerative medicine will play an increasingly important role, and moreover, the success of these therapies offers promising opportunities for previously untreated diseases areas.
SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: CDMOs Are Innovating for 21st-Century Medicine June 6, 2018
Contributor Cindy H. Dubin speaks with some of the industry’s leading CDMOs about the innovations they are developing for next-generation patient care, and how many are making investments that are enabling them to offer more services under one roof.
GSK Signs Strategic Agreement With Orchard Therapeutics April 11, 2018
GSK and Orchard Therapeutics today announced a strategic agreement, under which GSK will transfer its portfolio of approved and investigational...SPECIAL FEATURE - Analytical Testing - Contractors Take on the Challenge of Complex Molecules January 9, 2018
Contributor Cindy H. Dubin highlights some of the analytical testing services that leading contractors offer aimed at the increasing complexities of today’s pharmaceutical pipelines.
EXECUTIVE INTERVIEW - Particle Sciences: Experts in Development & Manufacturing of Complex Dosage Forms September 29, 2017
Dr. Mark Mitchnick, CEO of Particle Sciences and CMO of Lubrizol, discusses the rise of complex drug products, the capabilities needed to develop and manufacture these products, and the company’s expansion in this area.
